Quantcast

Perceptive Informatics® Global Survey Results Indicate Growing Demand for CTMS to Assist in More Efficient Site Monitoring and Management

May 19, 2011

BOSTON, May 19, 2011 /PRNewswire/ — Perceptive Informatics, the industry’s leading eClinical solutions provider and a subsidiary of PAREXEL International Corporation (NASDAQ: PRXL), today announced results of a global survey conducted during its webinar entitled “Critical Tasks of Site Monitors: Using a CTMS to Improve Efficiency.” Perceptive polled biopharmaceutical industry professionals across a broad range of clinical, data management and IT functions about the value of providing Clinical Research Associates (CRAs) with access to a Clinical Trial Management System (CTMS) to assist in site monitoring and management activities during clinical trials.

The survey results revealed that 89% of respondents provide CRAs with access to either a CTMS or other monitoring tool. The majority of these respondents combine other monitoring tools with a CTMS to achieve greater site monitoring and management efficiencies. A CTMS helps CRAs to view the status of a clinical trial, access patient data, and identify outstanding issues, as well as to make informed decisions about requirements for site visits. The remaining respondents (11%) provide no access to these types of systems.

“As site management is a key part of the CRA role, providing CRAs with access to the cross-study and cross-site data available within a CTMS is vital. There is growing recognition across the industry that when CRAs use sophisticated eClinical technologies they are more efficient in site monitoring and management activities,” said Liz Love, Product Manager of CTMS, Perceptive Informatics. “At Perceptive, we are focused on enabling more effective centralized and field-based monitoring through our CTMS to support an increasingly mobile and globalized CRA workforce.”

The IMPACT® MySites(TM) module, which is part of the IMPACT CTMS from Perceptive Informatics, is a complete site management and monitoring tool. The MySites module provides a view of key milestones, recruitment progress, and issue activity across all sites, allowing CRAs to seamlessly monitor workload and plan site visits, whether they are working online or offline. The IMPACT CTMS from Perceptive Informatics, an enterprise-wide solution used to plan, track, and report on clinical trials, is available as a hosted, software-as-a-service (SaaS) application and is part of the Perceptive Informatics eClinical Suite.

For more information about the IMPACT CTMS visit: http://www.perceptive.com/ctms/impact/. For more information about the eClinical Suite from Perceptive Informatics visit: http://www.perceptive.com/solutions/eclinical-suite/.

About Perceptive Informatics

Perceptive Informatics, a leading eClinical solutions provider and subsidiary of PAREXEL, is focused on helping customers to accelerate the product development process through innovation. Perceptive enables customers to maximize the benefits of clinical trial technologies by providing flexible software-as-a-service (SaaS) applications and leading technology services. The Perceptive Informatics eClinical Suite is built on extensive medical and clinical expertise, as well as a deep understanding of the regulatory environment. The suite includes Randomization and Trial Supply Management (RTSM) technologies, Medical Imaging, Clinical Trial Management Systems (CTMS), Electronic Data Capture (EDC), and Electronic Patient-Reported Outcomes (ePRO). The Perceptive Informatics eClinical Suite blurs the boundaries among systems that traditionally have been used in isolation, resulting in simplified workflow, improved efficiency and enhanced productivity. For more information about the integrated solutions in the Perceptive Informatics eClinical Suite visit www.perceptive.com.

About PAREXEL International

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 71 locations throughout 52 countries around the world, and has approximately 10,350 employees. For more information about PAREXEL International visit www.PAREXEL.com.

This release contains “forward-looking” statements regarding future results and events, including, without limitation, statements regarding expected financial results, future growth and customer demand. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. The Company’s actual future results may differ significantly from the results discussed in the forward-looking statements contained in this release. Important factors that might cause such a difference include, but are not limited to, risks associated with: actual operating performance; actual expense savings and other operating improvements resulting from recent and anticipated restructurings, the loss, modification, or delay of contracts which would, among other things, adversely impact the Company’s recognition of revenue included in backlog; the Company’s dependence on certain industries and clients; the Company’s ability to win new business, manage growth and costs, and attract and retain employees; the Company’s ability to complete additional acquisitions and to integrate newly acquired businesses or enter into new lines of business; the impact on the Company’s business of government regulation of the drug, medical device and biotechnology industry; consolidation within the pharmaceutical industry and competition within the biopharmaceutical services industry; the potential for significant liability to clients and third parties; the potential adverse impact of health care reform; and the effects of exchange rate fluctuations and other international economic, political, and other risks. Such factors and others are discussed more fully in the section entitled “Risk Factors” of the Company’s Quarterly Report on Form 10-Q for the quarter ended December 31, 2010 as filed with the SEC on February 9, 2011, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.

PAREXEL® and IMPACT® are registered trademarks of PAREXEL International Corporation, and Perceptive Informatics® is a registered trademark of Perceptive Informatics, Inc. All other names or marks may be registered trademarks or trademarks of PAREXEL International Corporation, Perceptive Informatics, Inc. or their respective owners and are hereby acknowledged.


    Contacts:
    Jennifer Baird, Senior Director of
     Public Relations                         Gene Carozza/Kim Baker
    PAREXEL International                     PAN Communications
    Tel: +781-434-4409                        Tel: +978-474-1900
    Email: Jennifer.Baird@PAREXEL.com         Email: PAREXEL@pancomm.com

SOURCE PAREXEL International Corporation


Source: newswire



comments powered by Disqus